ArticleCell biochemistry and biophysics2025
Mechanisms of Luteolin Against Gastro-Esophageal Reflux Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Luteolin Alleviates Inflammation Induced byVeterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin is a naturally occurring flavonoid. The effectiveness of luteolin-rich drugs in treating gastro-esophageal reflux disease (GERD) through traditional Chinese medicine has been demonstrated. This study aimed to identify the potential targets and mechanisms of action of luteolin for the treatment of GERD. An innovative approach combining network pharmacology and molecular dynamics was used to explore the potential therapeutic mechanisms of luteolin and to facilitate the further development of GERD treatment. Drug and disease target information was screened from public databases to obtain 159 intersecting targets through the construction of Venn diagrams. Subsequently, a protein‒protein interaction (PPI) network was constructed, and 10 core targets were identified. Through Gene Ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, relevant biological processes, cellular components, and molecular functions related to the treatment of GERD were identified and revealed. KEGG pathway analyses showed enrichment of signaling pathways, including the TNF, IL-17, NF-kappa B, and Toll-like receptor pathways. The molecular docking results indicated that luteolin can effectively bind to 10 core targets. Finally, molecular dynamics simulations confirmed the formation of stable protein‒ligand complexes when IL6 binds to luteolin. In conclusion, network pharmacology, molecular docking, and molecular dynamics simulations were utilized to investigate the mechanism by which luteolin treats GERD. These findings establish a theoretical foundation for future research on the efficacy of luteolin in treating GERD.
Indexed as
Identifiers
39180676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.